Revealing what makes bacteria life-threatening
Queensland researchers have discovered that a mutation allows some E. coli bacteria to cause severe disease in people while other bacteria are harmless, a finding that could help to combat antibiotic resistance.
Professor Mark Schembri and Dr Nhu Nguyen from IMB and Associate Professor Sumaira Hasnain from Mater Research found the mutation in the cellulose making machinery of E. coli bacteria. The research was published in Nature Communications.
Professor Schembri said the mutation gives the affected E. coli bacteria the green light to spread further into the body and infect more organs, such as the liver, spleen and brain.
"Bad' bacteria can't make cellulose
“Our discovery explains why some E. coli bacteria can cause life-threatening sepsis, neonatal meningitis and urinary tract infections (UTIs), while other E. coli bacteria can live in our bodies without causing harm,” Professor Schembri said.
“The ‘good’ bacteria make cellulose and ‘bad’ bacteria can’t.”
Bacteria produce many substances on their cell surfaces that can stimulate or dampen the immune system of the host.
Inflammation and spreading through the body
“The mutations we identified stopped the E. coli making the cell-surface carbohydrate cellulose and this led to increased inflammation in the intestinal tract of the host,” Professor Schembri said.
“The result was a breakdown of the intestinal barrier, so the bacteria could spread through the body.”
In models that replicate human disease, the team showed that the inability to produce cellulose made the bacteria more virulent, so it caused more severe disease, including infection of the brain in meningitis and the bladder in UTIs.
Finding new ways to prevent infection
Associate Professor Hasnain said understanding how bacteria spread from intestinal reservoirs to the rest of the body was important in preventing infections.
“Our finding helps explain why certain types of E. coli become more dangerous and provides an explanation for the emergence of different types of highly virulent and invasive bacteria,” she said.
Professor Schembri said E. coli was the most dominant pathogen associated with bacterial antibiotic resistance.
“In 2019 alone, almost 5 million deaths worldwide were associated with bacterial antibiotic resistance, with E. coli causing more than 800,000 of these deaths,” he said.
“As the threat of superbugs that are resistant to all available antibiotics increases worldwide, finding new ways to prevent this infection pathway is critical to reduce the number of human infections.”
This article was republished from the University of Queensland website. Read the original here.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.